Cognitive Impairment and Depression in Chronic Kidney Disease Patients

Cognitive function is crucial for independence and quality of life (QoL). Cognitive impairment (CI) is classified by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) into delirium, mild Neurocognitive Disorder (NCD), and major NCD (dementia), across six domains, including complex attention, executive function, and learning and memory. Prevention is key, as a significant portion of dementia cases are linked to modifiable risk factors. Chronic Kidney Disease (CKD) affects 8% to 16% globally and is an independent risk factor for cognitive decline. CI prevalence ranges from 10% to 40%, with function inversely related to Glomerular Filtration Rate (GFR). CI etiology is primarily cerebrovascular disease, specifically small-vessel disease, affecting processing speed and executive function, rather than increased Alzheimer’s pathology. Non-vascular factors include anemia, hyperparathyroidism, sleep apnea, and uremic toxicity, causing blood-brain barrier (BBB) breakdown.Depression is commonly observed among CKD patients, with prevalence rates three to four times higher than those in the general population. The relationship is bidirectional, driven by systemic inflammation (Interleukin-6 and Tumor Necrosis Factor-alpha). Crucially, the coexistence of CKD and depression exerts a significant synergistic effect on CI, intensifying neuroinflammatory responses and cerebral hypoxia-ischemia. Management must be comprehensive, controlling traditional cardiovascular risk factors, correcting severe anemia, treating secondary hyperparathyroidism, and implementing intensive blood pressure control.